BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell to make $3 million available to BriaPro to fund research and development efforts for sCD80 cancer treatment.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

BriaCell Therapeutics Corp. and its majority-owned subsidiary BriaPro Therapeutics Corp. have entered into a definitive purchase agreement where BriaPro will acquire BriaCell's exclusive license to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment. BriaPro will pay 2% royalties to the University of Maryland, Baltimore County upon commercialization, and BriaCell will make up to $3 million available to BriaPro to fund research and development efforts.

Why it matters

The sCD80 technology, originally developed by a researcher at the University of Maryland, Baltimore County, has shown promising anti-tumor activity in animal studies and the potential to restore natural anti-tumor immunity. This transaction allows BriaPro to accelerate the development of this novel cancer treatment approach.

The details

Under the terms of the agreement, BriaPro will gain worldwide rights to develop and commercialize sCD80 as a therapeutic agent for cancer treatment, while the university retains certain rights. BriaPro will pay 2% royalties to the university upon commercialization. As part of the deal, BriaCell will make up to $3 million available to BriaPro to fund research and development efforts. In exchange, BriaPro will issue 23,972,589 common shares to BriaCell, increasing BriaCell's ownership in BriaPro to approximately 78% post-transaction.

  • BriaCell originally secured the exclusive license from the University of Maryland, Baltimore County on August 2, 2022.
  • The transaction is expected to close on or around March 12, 2026.

The players

BriaCell Therapeutics Corp.

A clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

BriaPro Therapeutics Corp.

A pre-clinical stage immunotherapy company developing binding agents and proteins to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors.

University of Maryland, Baltimore County

The university that originally developed the Soluble CD80 (sCD80) technology and holds the patents for it.

Suzanne Ostrand-Rosenberg, Ph.D.

Emeritus Faculty at the University of Maryland, Baltimore County and member of BriaCell's scientific advisory board, who originally developed the sCD80 technology.

William V. Williams, MD

President and CEO of BriaCell and BriaPro.

Got photos? Submit your photos here. ›

What they’re saying

“Our mission has been to develop safe and effective treatments for cancer patients who do not respond to existing treatments, and a transformational anti-cancer agent such as sCD80 may provide us with such an additional opportunity.”

— William V. Williams, MD, President and CEO, BriaCell and BriaPro (BriaCell Press Release)

What’s next

The transaction is expected to close on or around March 12, 2026, subject to certain conditions including approval of the disinterested shareholders of BriaPro and receipt of a third-party valuation confirming the transaction is occurring at fair market value.

The takeaway

This transaction allows BriaPro to accelerate the development of the promising sCD80 technology, which has shown potential to restore natural anti-tumor immunity and provide a new treatment option for cancer patients who do not respond to existing therapies.